Developments FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program Cumberland Pharmaceuticals (NASDAQ: CPIX) has received Fast Track Designation from the FDA for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA has... February 4, 2026